Early diagnosis and treatment of breast cancer in Japanese kidney transplant recipients: a single center experience
- PMID: 25992308
- PMCID: PMC4431989
- DOI: 10.1186/s40064-015-0946-2
Early diagnosis and treatment of breast cancer in Japanese kidney transplant recipients: a single center experience
Abstract
Background: The incidence of malignancies in kidney transplant recipients is increasing. Breast cancer is a common malignancy after kidney transplantation and can be more aggressive in kidney transplant recipients than in the general population. In this study, we evaluated the incidence and prognosis of breast cancer in kidney transplant recipients.
Findings: Between 1993 and 2013, 750 kidney transplant patients were followed-up at our center. Since 1999, annual physical examination, mammography, and breast ultrasonography have been performed for such patients. Diagnostic studies, including core needle or mammotome biopsy, were performed for suspected malignancies. Patients with malignant neoplasm were administered the appropriate treatment and followed-up to assess tumor response and symptoms. Nine patients were diagnosed with breast cancer during the follow-up period. The mean age at the initial detection of the breast cancer was 47.7 ± 8.4 years. The mean interval from transplantation to diagnosis was 148.7 ± 37.1 months. Of the 9 patients, 8 were detected through the screening test; 7 were treated with breast conservative surgery and 1 was treated with modified radical mastectomy. The cancer stages were 0 (n = 2), I (n = 6), and II (n = 1). The incidence of breast cancer tended to be unchanged with time between transplantation and diagnosis, inconsistent with the increase in the duration of immunosuppression.
Conclusion: Annual screening tests are crucial in the early diagnosis of breast cancer. Early treatment of breast cancer can result in an excellent prognosis in kidney transplant recipients.
Keywords: Breast cancer; Kidney transplantation; Prognosis; Screening.
Figures
Similar articles
-
The benefits of cancer screening in kidney transplant recipients: a single-center experience.Cancer Med. 2016 Feb;5(2):153-8. doi: 10.1002/cam4.568. Epub 2015 Dec 21. Cancer Med. 2016. PMID: 26686199 Free PMC article.
-
Responding to the challenges of breast cancer in egypt and other arab countries.J Egypt Natl Canc Inst. 2008 Dec;20(4):309-12. J Egypt Natl Canc Inst. 2008. PMID: 20571588
-
Thyroid disease and cancer in kidney transplantation: a single-center analysis.BMC Surg. 2019 Apr 24;18(Suppl 1):80. doi: 10.1186/s12893-018-0408-1. BMC Surg. 2019. PMID: 31074392 Free PMC article.
-
[Early de novo neoplasia after renal transplantation].Tumori. 2003 Jul-Aug;89(4 Suppl):301-4. Tumori. 2003. PMID: 12903627 Review. Italian.
-
Cancer in kidney transplant recipients.Nat Rev Nephrol. 2018 Aug;14(8):508-520. doi: 10.1038/s41581-018-0022-6. Nat Rev Nephrol. 2018. PMID: 29802400 Review.
Cited by
-
Synergy in combining findings from mammography and ultrasonography in detecting malignancy in women with higher density breasts and lesions over 2 cm in Albania.Contemp Oncol (Pozn). 2016;20(6):475-480. doi: 10.5114/wo.2016.65608. Epub 2017 Jan 12. Contemp Oncol (Pozn). 2016. PMID: 28239286 Free PMC article.
-
[Gynecological cancers in patients with inflammatory rheumatic diseases].Z Rheumatol. 2016 Feb;75(1):63-7. doi: 10.1007/s00393-016-0044-z. Z Rheumatol. 2016. PMID: 26813689 Review. German.
References
-
- Alberu J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES, Sirolimus CONVERT Trial Study Group Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation. 2011;92:303–310. doi: 10.1097/TP.0b013e3182247ae2. - DOI - PubMed
-
- Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–529. doi: 10.1056/NEJMoa1109653. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources